Many diseases, including pulmonary arterial hypertension, cut across various medical specialties and require multidisciplinary cooperation.
Pulmonary arterial hypertension, once considered a disease of the young, is increasingly affecting patients of older age.
Although our understanding of PAH has significantly improved, we are still far away from a definitive cure.
Researchers are increasingly exploring the potential of gene therapy in treating respiratory diseases.
Clinical researchers are emphasizing the value of exercise in alleviating the symptoms of some diseases, including pulmonary arterial hypertension (PAH).
Members of the general public generally recognize carbon monoxide (CO) as a toxic gas that can be lethal if a person is exposed to large quantities of it over a short period of time. CO poisoning is insidious because the gas itself is colorless, tasteless, and odorless, making it harder to detect. In a study…
Beta-blockers may have different effects in the early stages of pulmonary arterial hypertension than in later stages of the disease.
We discuss the challenges of treating pediatric patients with PAH, especially the scarcity of clinical data specific to children.
The progressive changes associated with PAH predispose patients to developing hemoptysis, especially when congenital heart disease is also present.
We explore the vast medical challenge of treating the combination of idiopathic pulmonary fibrosis and pulmonary hypertension successfully.